Title:
The translocation and mutant ROS kinase in human non-small cell lung cancer
Document Type and Number:
Japanese Patent JP6259320
Kind Code:
B2
Abstract:
In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter lsoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
More Like This:
Inventors:
Island quart
Anthony Possemato
Anthony Possemato
Application Number:
JP2014041462A
Publication Date:
January 10, 2018
Filing Date:
March 04, 2014
Export Citation:
Assignee:
Cell Signaling Technology Incorporated
International Classes:
C12N15/09; C07K14/47; C07K19/00; C12N9/12; C12Q1/48; C12Q1/68
Foreign References:
| WO2007084631A1 |
Attorney, Agent or Firm:
Kawaguchi International Patent Office
Previous Patent: The film production solution constituent for hollow fibers
Next Patent: MICROCOMPUTER
Next Patent: MICROCOMPUTER